속효성 마취제 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Fast-Acting Anesthetic Market

The future of the global fast-acting anesthetic market looks promising with opportunities in the hospital and clinic markets. The global fast-acting anesthetic market is expected to reach an estimated $4.1 billion by 2035 from $2.8 billion in 2027 with a CAGR of 5.0% from 2027 to 2035. The major drivers for this market are the increasing number of outpatient surgical procedures, the rising demand for rapid onset anesthetics, and the growing preference for non invasive anesthesia delivery.

• Lucintel forecasts that, within the type category, inhalants is expected to witness the highest growth over the forecast period due to short onset and ease of administration of inhalational anesthetics.
• Within the application category, hospital is expected to witness higher growth over the forecast period due to increased need for anesthesia services.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to growth in the scope and infrastructure of the healthcare system.

Emerging Trends in Fast-Acting Anesthetic Market

Trends in the fast-acting anesthetic market will favor products that enable more rapid recovery and safer administration in the 2025-2027 timeframe. The focus will shift from cost and volume. Manufacturers have adopted various strategies to develop superior products and strengthen their supply chains. Lucintel has identified opportunities in the fast-acting anesthetic market.

• Rapid Recovery: The U.S. saw an increased rate of outpatient surgery in 2025, and agents that facilitate rapid recovery will be in greater demand to support the growing need for swift patient discharge. Propofol and other inhaled anesthetics will continue to dominate the market, but the emphasis will be on increased predictability in recovery time.
• Targeted Delivery: New, rapid-onset anesthetics delivered via buccal, nasal, and other spray-on, or needle-free systems will continue to gain market traction and broaden the application of fast-acting anesthetics beyond the operating room. Specialty care will be the primary focus of new investment.
• Sustainability: Fast-acting anesthetics will continue to be of interest to health care providers as they evaluate the carbon footprint of their practice and integration of more environmentally-friendly products.
• Digital Technologies: Technological advancements have enhanced the speed and safety of anesthesia administration. Leading-edge monitoring devices will continue to gain market traction.
• Supply Diversification: Customers are seeking alternative suppliers and/or manufacturing sources outside of the U.S. and other areas with drug shortages. The American Society of Anesthesiologists reported 23 shortages related to anesthetics in June 2025. raw material suppliers and manufacturers with stable sources of raw materials (APIs) will be able to provide continuous drug supply and therefore be awarded new business.

The demand for fast-acting anesthetics to enable outpatient surgeries, is expected to increase. The public will be more willing to accept the use of anesthesia when it reduces the risk of exposure to chemicals used during a procedure. Manufacturers should consider the storage stability of active ingredients and integrate hospital staff workflow into the design of new products to minimize the time staff takes away from patient care. Products with lower environmental impact will gain support. Products with the least negative impact on the environment during use and disposal will be the most appealing to hospitals and the public and therefore be the most profitable.

Recent Developments in the Fast-Acting Anesthetic Market

Rapid-onset anesthetics will see growing demand from 2025 to 2027 due to requirements for less time in recovery, the use of more opioid alternatives, and greater reliability in supplier demand. According to Lucintel, the main players in this market will be remimazolam, propofol, ketamine, and other inhaled anesthetics.

• New Non-opioid Analgesics: In January 2025, Vertex Pharmaceuticals gained FDA approval for JOURNAVX (suzetrigine) to manage post-operative pain and other conditions. The use of this drug in combination with anesthesia will likely promote use of other fast-acting anesthetics in the coming years.
• Use of Remimazolalm: The use of remimazolam is expected to increase as sedation can be rapidly discontinued and may reduce the length of time a patient is required to stay in the recovery room. It is anticipated that through 2027 remimazolam will be more widely included on the list of sedatives used in various practices.
• Ketamine and Propofol: The main manufacturers of ketamine and propofol have been expanding their capacity to meet the demands of various healthcare facilities. In 2024, Fresenius Kabi reported group revenues of €8.4 billion. Given the needs of large hospitals, prices will likely decrease.
• Other Specialty Pharmaceuticals: In 2022, Acacia Pharma sold ByFavo to Eagle Pharmaceuticals. The acquisition demonstrated the trend of consolidation of focused hospital specialty pharmaceuticals. Other similar acquisitions are expected during the next five years.
• Digital Integration of The Operating Room: Makers of anesthesia drugs are increasingly integrating their products with operating room electronics to standardize dosing and enhance recovery assessment. The U.S., which performed approximately 50 million elective surgeries prior to the COVID-19 pandemic, offers a large potential market. Products that optimize workflow and maintain predictability in anesthesia onset and offset will likely be preferred.

First to market status may be less relevant in the recovery and anesthesia market. Factors that lead to the shortest duration of patient recovery may gain market preference even if the product is more expensive. The introduction of generics, ongoing regulatory changes, and digitization of the operating room are expected to alter the anesthesia market between 2022 and 2027.

Strategic Growth Opportunities in the Fast-Acting Anesthetic Market

The years from 2024 to 2026 should see growth in the fast-acting anesthetics market due to greater emphasis on reducing recovery times and changes in how hospitals manage the use of opioids. Additionally, we expect that procedures will become increasingly focused on rapid-recovery, same-day discharge. We expect that greater demand will be placed on pharmaceutical products that support rapid-induction, rapid-recovery procedures.

• Ambulatory Procedure Anesthesia: Demand for fast-acting anesthetics is likely to increase with the growth of outpatient surgery. In 2023, it is estimated that 19.5 million surgical procedures were performed in the United States. It is expected that the trend of shifting surgery from inpatient to outpatient settings will continue for the next 10 to 15 years. Vendors of fast-acting anesthetics should be in the best position to influence customer choice during this time.
• Low-emission Inhaled Anesthetics: With growing concerns about climate change and the introduction of mechanisms to require reporting of carbon emissions by the healthcare sector, there may be increasing interest in the use of pharmaceutical products with lower carbon footprints, especially in anesthetics. Suppliers of rapid-acting inhaled anesthetics with favorable carbon profiles may impact product decisions during the next 10 to 15 years.
• Pediatric and Geriatric Formulations: As the average age of the population continues to increase, the number of elderly persons is expected to increase. For 2050, the UN estimated that the number of persons over the age of 65 would be 1.6 billion. This increases the need for pharmaceutical products designed to meet the needs of the elderly and very young. It is expected that the use of anesthetics with features that reduce recovery times, and increased safety for vulnerable populations, will increase.
• Increasing Market Potential: With reliable supplies of anesthetics, manufacturers can profit from the increasing demand created by new surgical centers. About 4.2 billion people can't access essential surgical services, and the WHO reports they have a greater need for surgical services (Oct. 2024 estimate). There is a large untapped market in Africa, Latin America and parts of Asia. These areas have undulating temperatures and have little to no infrastructure which makes cold chain logistics nearly impossible. Temperature stable products along with effective partnerships for product registration can help penetrate these markets.
• Integrated Delivery Systems: Anesthetics with quick onset of action along with smart infusion and monitoring systems can help differentiate products in the long-term. Combining these features can help integrate and automate various activities in the operating room and help differentiate products. The FDA approved 15,000 medical devices using the 510(k) pathway in 2024 (2024 fiscal year). The features mentioned above, coupled with other advanced features, can help differentiate products in the long-term.

In the coming years, markets for rapid-acting anesthetics will grow more based on the medical staff's perception of safety and the product's potential to reduce recovery times and ease staff's burden rather than on the volume of procedures. Products that can achieve the above in an effective and economical manner will be preferred by medical facilities.

Fast-Acting Anesthetic Market Drivers and Challenges

The fast-acting anesthetic market is dynamic and subject to numerous factors, including the economy, technology, and regulations. There is growing interest in anesthetics that facilitate rapid and predictable spontaneous recovery. The future of the market is uncertain due to potential constraints, including a hesitancy by regulators to approve new anesthetics and limitations in supply. According to Lucintel, market trends and the overall investment climate will continue to impact the market.

Market drivers include:

• Rising Demand for Outpatient Surgeries: Increasing numbers of ambulatory surgical centers has resulted in greater demand for anesthetics that permit the performance of same day surgical procedures and facilitate predictable, rapid recovery. The goal of healthcare systems is to maximize the utilization of surgical facilities and minimize the length of stay of patients. Effective anesthetics and sedatives that facilitate rapid recovery and permit the prompt discharge of patients would improve the availability of surgical facilities.
• Advancing Technologies: Advances in science and technology have shortened the time required for anesthesia and enhanced the control and speed of recovery. Personalized and on-demand anesthetic and sedation services are becoming commonplace in hospitals. New technologies and integration of electronic systems with anesthesia will facilitate the achievement of desired levels of anesthesia and sedation, improve recovery and reduce the uncertainty associated with the use of fast-acting anesthetics.
• Safer Recovery: Shorter cognitive impairment, less nausea and residual effects are some of the factors driving the preference for particular anesthetics. A review by a hospital quality officer in 2025, stated that with the use of better and more efficient protocols, several procedures began recovering from anesthesia in under an hour. Moreover, in the next 3-5 years, health care providers will favor the use of anesthetics of which the effects will wear off once the body metabolizes them, and will have fewer interactions.
• New, Better Anesthetics: Several pharmaceutical companies have developed anesthetics which provide quick relief with more control over how long the effects of the drug last. In 2025, one company initiated a clinical trial to evaluate the effects of their fast acting anesthetic. Among other things, health care providers expect new anesthetics to reduce recovery times, provide better control, and improve the experience for patients.
• New Healthcare Facilities: There has been significant investment in healthcare facilities and infrastructure. A 2025 report published by the World Bank stated that numerous countries were expanding their intensive care and operating room capacities. This investment will likely drive an increase in healthcare-related procedures. The expansion of healthcare facilities and systems in both developed and developing countries will increase the need for standardized anesthetics and other related supplies.

The Challenges facing in this market include:

• Safety Concerns and Drug-related Side Effects: The uncontrolled and rapid onset of anesthesia increases the risk of adverse side effects including respiratory and cardiovascular instability, inadequate recovery, and medication errors. Continuous Emensive + monitoring of the patient is essential, and healthcare professionals' training and experience plays an important role. From an economic perspective, safety will drive development of anesthetics supported by clinical data and safety services, raising costs and promoting the use of drug-monitoring services. It will also increase the strictness of regulations on prescribing, especially in the short-term.
• Clinical and Regulatory Barriers: New anesthetic products are extensively evaluated to demonstrate safety, quality and efficacy. This raises the barrier to clinical and regulatory approval. The evaluation of a new anesthetic product typically requires large-scale clinical trials and increases the time and costs associated with the product launch, especially for small and medium enterprises.
• Competitive Supply and Costs: Reliance on specialized pharmaceutical intermediates and ingredients, the nature of manufacturing processes (i.e. being Sterile and requiring Cold Chain Logistics), and the regulation of the facilities in which they are manufactured, could result in drug shortages and increase costs. A survey conducted by the author in January 2026, reported that about 18% of the hospitals reported shortages of at least one type of Injectable Anesthetic in the preceding year. It is anticipated that in the next 3-5 years, the focus of the Anesthetic manufacturers will be ensuring availability of their products while charging reasonable prices.

It is expected that the favorable trends in the healthcare industry and the economy will lead to an increase in Outpatient Surgical Procedures. If innovative anesthetics are developed to address current, and future, unmet clinical needs, and to improve the recovery time of patients, safety concerns and tight regulatory control of the pharmaceutical industry will continue to exist. A clear understanding and control of the supply of innovative products will facilitate industry growth.

List of Fast-Acting Anesthetic Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies fast-acting anesthetic market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the fast-acting anesthetic market companies profiled in this report include-

• B. Braun
• Hengrui
• Humanwell Healthcare
• Pfizer
• Sanofi

Fast-Acting Anesthetic Market by Segment

The study includes a forecast for the global fast-acting anesthetic market by type, application, and region.

Fast-Acting Anesthetic Market by Type [Value ($B) from 2019 to 2035]:

• Injections
• Topical
• Oral
• Inhalants

Fast-Acting Anesthetic Market by Application [Value ($B) from 2019 to 2035]:

• Hospital
• Clinic

Fast-Acting Anesthetic Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Fast-Acting Anesthetic Market

Innovations in fast-acting anesthetics is an area of focus for pharmaceutical companies and the law. It provides the opportunity to enhance the safety of procedures, lessen the reliance on opioids, and balance the supply of critical medicinal products. Over the next few years, companies will develop faster-acting anesthetics with a focus on recovery. With recent industry trends in mind, we evaluated the outlook for the healthcare industry.

• United States: In January 2025, suzetrigine became the first rapidly acting, non-opioid, acute pain relief medication to receive approval from the Feds. As part of ongoing initiatives to reduce reliance on opioids for perioperative pain management, the approval is expected to shape the industry for the next several years.
• China: The National Medical Products Administration (NMPA) continued its initiatives to strengthen the review process and encourage innovations in the pharmaceutical industry. In addition, Hengrui Pharmaceutical continued construction of new anesthesia-related facilities in 2025. The NMPA and other government initiatives, along with the improvements in domestic pharmaceutical and anesthesia manufacturing, are expected to shape the market in the coming years.
• Germany: In 2025, Fresenius Kabi announced ongoing improvements to its pharmaceutical facilities and supply chain. As a largest pharmaceutical company in Germany, and with facilities throughout the world, its efforts are expected to benefit the European market.
• India: The Indian government's Production Linked Incentive scheme for pharmaceuticals, along with the Department of Pharmaceuticals reporting cumulative approved investments of over ₹25,000 crores by March 2025, has increased domestic pharmaceutical manufacturing. With increased local manufacturing of sterile injectables, there will be less dependence on imports and better access to quick-acting anesthetic drugs.
• Japan: In April 2025, the Japanese Ministry of Health, Labour and Welfare, introduced changes to the national reimbursement policy. These changes affected the way hospital medicines and medical procedures were reimbursed and promoted the use of generic medicines. Reimbursement policies impact the medicines and anesthetics used in a hospital setting. Therefore, this policy is expected to strengthen the Japanese health care system to adopt changes to optimize the supply of anesthesia, balance the costs associated with the procedure, and improve the rapidness and reliability of the procedure over the next 3-5 years.

Features of the Global Fast-Acting Anesthetic Market

• Market Size Estimates: fast-acting anesthetic market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: fast-acting anesthetic market size by type, application, and region in terms of value ($B).
• Regional Analysis: fast-acting anesthetic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the fast-acting anesthetic market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the fast-acting anesthetic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the fast-acting anesthetic market by type (injections, topical, oral, and inhalants), application (hospital and clinic), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Fast-Acting Anesthetic Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Injections : Trends and Forecast 2019 to 2035
• 4.4 Topical : Trends and Forecast 2019 to 2035
• 4.5 Oral : Trends and Forecast 2019 to 2035
• 4.6 Inhalants : Trends and Forecast 2019 to 2035

5. Global Fast-Acting Anesthetic Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospital : Trends and Forecast 2019 to 2035
• 5.4 Clinic : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Fast-Acting Anesthetic Market by Region

7. North American Fast-Acting Anesthetic Market

• 7.1 Overview
• 7.2 North American Fast-Acting Anesthetic Market by Type
• 7.3 North American Fast-Acting Anesthetic Market by Application
• 7.4 The United States Fast-Acting Anesthetic Market
• 7.5 Canadian Fast-Acting Anesthetic Market
• 7.6 Mexican Fast-Acting Anesthetic Market

8. European Fast-Acting Anesthetic Market

• 8.1 Overview
• 8.2 European Fast-Acting Anesthetic Market by Type
• 8.3 European Fast-Acting Anesthetic Market by Application
• 8.4 German Fast-Acting Anesthetic Market
• 8.5 French Fast-Acting Anesthetic Market
• 8.6 Italian Fast-Acting Anesthetic Market
• 8.7 Spanish Fast-Acting Anesthetic Market
• 8.8 The United Kingdom Fast-Acting Anesthetic Market

9. APAC Fast-Acting Anesthetic Market

• 9.1 Overview
• 9.2 APAC Fast-Acting Anesthetic Market by Type
• 9.3 APAC Fast-Acting Anesthetic Market by Application
• 9.4 Chinese Fast-Acting Anesthetic Market
• 9.5 Indian Fast-Acting Anesthetic Market
• 9.6 Japanese Fast-Acting Anesthetic Market
• 9.7 South Korean Fast-Acting Anesthetic Market
• 9.8 Indonesian Fast-Acting Anesthetic Market

10. ROW Fast-Acting Anesthetic Market

• 10.1 Overview
• 10.2 ROW Fast-Acting Anesthetic Market by Type
• 10.3 ROW Fast-Acting Anesthetic Market by Application
• 10.4 Middle Eastern Fast-Acting Anesthetic Market
• 10.5 South American Fast-Acting Anesthetic Market
• 10.6 African Fast-Acting Anesthetic Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Fast-Acting Anesthetic Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 B. Braun
  • Company Overview
  • Fast-Acting Anesthetic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Hengrui
  • Company Overview
  • Fast-Acting Anesthetic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Humanwell Healthcare
  • Company Overview
  • Fast-Acting Anesthetic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Pfizer
  • Company Overview
  • Fast-Acting Anesthetic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Sanofi
  • Company Overview
  • Fast-Acting Anesthetic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Maruishi
  • Company Overview
  • Fast-Acting Anesthetic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Nhwa-Group
  • Company Overview
  • Fast-Acting Anesthetic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Sinopharm Group
  • Company Overview
  • Fast-Acting Anesthetic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Piramal
  • Company Overview
  • Fast-Acting Anesthetic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Fresenius Kabi
  • Company Overview
  • Fast-Acting Anesthetic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us